PFE vs XOM: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and Exxon Mobil Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
VS
Exxon Mobil Corporation · Energy
$154.46
-40.5% upside to fair value
Grade C
QuantHub Verdict
PFE has more upside to fair value
(+28.6%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
XOM |
| Current Price |
$26.33 |
$154.46 |
| Fair Value Estimate |
$33.85 |
$91.87 |
| Upside to Fair Value |
+28.6%
|
-40.5%
|
| Market Cap |
$149.8B |
$642.0B |
| Forward P/E |
19.3x
|
23.2x
|
| EV / EBITDA |
12.9x
|
10.3x
|
| Price / Sales |
2.4x
|
2.0x
|
| Price / FCF |
16.5x
|
27.2x
|
| Revenue Growth YoY |
-1.2%
|
-1.3%
|
| Gross Margin |
70.3%
|
21.7%
|
| Operating Margin |
24.7%
|
10.5%
|
| Return on Equity |
8.7%
|
11.0%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
6.06%
|
3.68%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Exxon Mobil Corporation operates as a global integrated oil and gas company with significant operations in upstream, energy products, chemical products, and specialty products segments. The company benefits from a highly experienced management team with decades of internal tenure, led by CEO Darren Woods. Despite strong cash flow generation and operational scale, Exxon is currently overvalued, tr…
Accumulation Zones
| Metric |
PFE |
XOM |
| Zone Low |
$25.39 |
$68.90 |
| Zone High |
$28.77 |
$78.09 |
| In Buy Zone? |
Yes
|
No
|